16 October 2014

Company Announcements Office
Australian Securities Exchange

Quarterly conference call: AMENDED dial in details

Please note below updated details for the Nanosonics (ASX.NAN) conference call to be held on Monday, October 20, 2014 at 11.00am ADST.

The call will cover the latest Appendix 4C released by Nanosonics (ASX.NAN) to the ASX today.

The amended conference call details are:

Conference ID: 257 970

Dial in numbers:

Australia	1800 558 698
Canada	1855 8811 339
China	4001 200 659
Hong Kong	800 966 806
India	0008 0010 08443
Japan	0053 116 1281
New Zealand	0800 453 055
Singapore	800 101 2785
United Kingdom	0800 051 8245
United States	1855 8811 339

An archive of the call will be available at**:** http://www.openbriefing.com/OB/1611.aspx
and on the company's website: www.nanosonics.com.au

Michael Kavanagh
CEO / President

For more information please contact:
Michael Kavanagh, CEO / President or McGregor Grant, CFO, on (02) 8063 1600
Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722 / kwilliamson@buchanwe.com.au
Ben Oliver, Media Relations, Buchan Consulting on (03) 9866 4722 / boliver@buchanwe.com.au

About Nanosonics
Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries. For more information about Nanosonics please visit www.nanosonics.com.au